Prosecution Insights
Last updated: November 12, 2026
Application No. 19/036,127

COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS

Non-Final OA §101§102§103§DP
Filed
Jan 24, 2025
Priority
Sep 19, 2017 — provisional 62/560,318 +3 more
Examiner
NGUYEN, NGHI V
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Advaxis Inc.
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
265 granted / 494 resolved
-6.4% vs TC avg
Strong +51% interview lift
Without
With
+50.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
48 currently pending
Career history
544
Total Applications
across all art units

Office Action

§101 §102 §103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-13 are pending (claim set as filed on 01/24/2025). Priority This application is a DIV of application no.: 17/503,647 (now U.S. Patent no. 12,239,738 B2), which is a DIV of application no.: 16/647,977 (now U.S. Patent no. 11,179,339 B2), which is a 371 of PCT/US2018/048586 filed on 08/29/2018, which has a provisional application no.: 62/560,318 filed on 09/19/2017. Information Disclosure Statement No Information Disclosure Statement (IDS) has been filed in this application. Applicant is reminded that each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the U.S. Patent and Trademark Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability (see 37 C.F.R. §1.56). Drawings The drawings filed on 01/24/2025 have been accepted. Claim Rejections - 35 USC §101, Subject Matter Eligibility 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-5 are rejected under 35 U.S.C. 101 because they are drawn to ineligible subject matter (based on the 2019 Revised Patent Subject Matter Eligibility Guidance). STEP 1: Is the claim directed to a process, machine, manufacture, or a composition of matter? YES, the claims are directed to a process of preparing a frozen Listeria for lyophilization, comprising thawing the frozen Listeria strain at a temperature between about 20-37°C. Note that the claims are interpreted under the broadest reasonable interpretation (BRI) standard. The lyophilization is an intended purpose and not a step that is required to practiced or exercised. STEP 2A: PRONG ONE: Does the claim recite an abstract idea, law of nature, or natural phenomenon? YES, the claims recite at least one judicially recognized exception(s) of: laws of nature, natural phenomena, and/or products of nature. The MPEP 2106.04(b) states “Laws of nature and natural phenomena, as identified by the courts, include naturally occurring principles/relations and nature-based products that are naturally occurring or that do not have markedly different characteristics compared to what occurs in nature”. The judicial exceptions of base claim 1 are: product of nature: the Listeria strain is a naturally occurring microorganism. natural phenomena: the act or step of “thawing” is a naturally occurring process in nature dependent upon the environmental conditions. PRONG TWO: Does the claim recite additional elements that integrate the judicial exception into a practical application? NO, the exception is not integrated into a practical application of the exception. The additional elements or a combination of elements in the claims does not impose a meaningful limit on the judicial exception. For example, the claims stop after the judicial exception and thus, it does not apply or use the judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition (see Vanda Memo). STEP 2B: Does the claim recite additional elements that amount to significantly more than the judicial exception? NO, the claimed invention is directed to laws of nature, natural phenomena, and/or products of nature without significantly more. The claim(s) does recite temperature ranges and thawing duration. However, these additional elements do not pose a meaningful limit on the judicial exceptions because the ranges are naturally occurring conditions in nature. Further, the step of thawing is recited at a high level of generality such that it amounts to insignificant pre-solution activity. Even when viewed as a combination, the additional elements fail to transform the exception into a patent-eligible application of that exception. The claim here does not invoke any of the considerations that courts have identified as providing significantly more than the exception. Therefore, when the additional elements are viewed as an ordered combination, they are not deemed to add meaningful limits on the use of the exception. Therefore, the claims, as a whole, are considered as processes directed to judicially recognized exceptions without amounting to significantly more from what occurs in nature and thus, are not eligible subject matter under 35 U.S.C. §101. Claim Rejections - 35 USC §102, Anticipation The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sweeney (US 2006/0121053 A1). Sweeney’s general disclosure relates to fed-batch methods for bioreactor production of high cell densities of Listeria which may be used as whole cells in vaccines (see ¶ [0002]). Regarding claims 1-5, Sweeney teaches “A 1 mL vial of Listeria was thawed from -80°C into 50-100 mLs of inoculum expansion medium in a 500 mL vented-cap shake flask. This culture was expanded overnight in a shaker/incubator at 37°C and 200 RPM” (see ¶ [0167]-[0168]). Claim Rejections - 35 USC §103, Obviousness The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or non-obviousness. Claims 6-13 are rejected under 35 U.S.C. 103 as being unpatentable over Sweeney as applied to the claims above, and in view of Deb (US 2018/0363002 A1). Sweeney is taught above as it pertains to a method of thawing a Listeria strain. Regarding the Listeria strain, Sweeny teaches any Listeria strain whether naturally occurring or recombinant may be used (see ¶ [0012]). Sweeney teaches Listeria monocytogenes (see ¶ [0003], [0020], [0029], [0064], [0185]). However, Sweeny does not teach: wherein the frozen Listeria strain is thawed in a formulation comprising a buffer and sucrose at 1-5% (claims 6-9 and 13). Deb’s general disclosure relates to preparations that exhibit improved transducing capabilities and storage stability (see ¶ [0001]). Regarding the thawing, Deb teaches the aqueous composition “maintains a concentration after 3 freeze/thaw cycles of from about 70% to about 100% relative to the concentration of said lentiviral vector in said aqueous composition prior to said freeze/thaw cycles, wherein each of said freeze/thaw cycles comprises freezing said aqueous composition and subsequently allowing said aqueous composition to thaw at room temperature” (see ¶ [0022] and claim 44). Deb further teaches “the mixture can remain frozen, e.g., for a period of one or more days, weeks, months, or years prior to thawing. The thawing step can be performed by exposing the mixture to conditions in which the temperature is from about 2°C to about 8°C., or by storing the mixture at room temperature (e.g., the ambient temperature of a laboratory, or about 25° C.). Alternatively, thawing can take place by use of a water bath (e.g., at 37°C)” (see ¶ [0033]). Regarding claim 6-9 pertaining to the buffer and sucrose, Deb teaches an aqueous composition that comprises a buffer and a carbohydrate selected from sucrose at a concentration of from about 1-10%, or in particular, 2.5% sucrose by weight per volume of the aqueous composition (see ¶ [0010]-[0012]). Deb teaches a buffer selected from the group consisting of a phosphate buffer, a sodium citrate, et. al. (see ¶ [0022], [0031]). Regarding claims 10-11 and 13 pertaining to the formulation being free of rHSA, Deb teaches the aqueous compositions are free of one or more proteins selected from the group consisting of human serum albumin (HSA), recombinant human serum albumin (rHSA) (see ¶ [0018]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to thaw in a formulation comprising a buffer and sucrose such as taught by Deb in the method of Sweeney. The ordinary artisan would have been motivated to do so is because Deb teaches an aqueous composition comprising a buffer and sucrose that offers storage stability. The ordinary artisan would have had a reasonable expectation of success because both references are directed to thawing and lyophilization of biological products. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1-13 are rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1, 4, 6-7, 10-11, and 22-23 of U.S. Patent no. 11,179,339 B2 (parent application no. 16/647,977). Although the claims at issue are not identical, they are not patentably distinct from each other because patent ‘339 are the narrower claims that anticipate the broader instant claims. Regarding claims 1 and 6, patent ‘339 teaches a method for producing a lyophilized composition comprising a Listeria strain, comprising thawing a frozen Listeria strain in a formulation comprising a buffer and sucrose (see claims 1 and 4 of patent ‘339). Regarding claims 2-3 pertaining to the temperature, patent ‘339 teaches the frozen Listeria strain is thawed at about 20-37°C (see claim 6 of patent ‘339). Regarding claims 4-5 pertaining to the thawing duration, patent ‘339 teaches wherein the frozen Listeria strain is thawed for no more than 8 hours and/or wherein the frozen Listeria strain is held at about 2-8°C for no more than 24 hours after thawing (see claim 7 of patent ‘339). Regarding claims 7-9 pertaining to the sucrose amount, patent ‘339 teaches wherein the formulation comprises about 1-5% w/v sucrose, about 2-3% w/v sucrose, or about 2.5% w/v sucrose (see claim 10 of patent ‘339). Regarding claims 10-13 pertaining to the formulation components, patent ‘339 teaches wherein the Listeria strain is a recombinant Listeria monocytogenes strain, and wherein the buffer is a phosphate buffer, and wherein the formulation comprises about 2-3% w/v sucrose, and wherein the formulation does not comprise trehalose, MSG, or rHSA (see claims 11 and 22-23 of patent ‘339). Conclusion No claims were allowed. Correspondence Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to NGHI V NGUYEN whose telephone number is (571)270-3055. The examiner can normally be reached Mon-Fri: 9 - 3 pm (ET). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached on (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NGHI V NGUYEN/Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Jan 24, 2025
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790588
SKIN TISSUE
3y 2m to grant Granted Nov 10, 2026
Patent 12758967
PRODUCTS AND METHODS TO ISOLATE MITOCHONDRIA
4y 0m to grant Granted Oct 13, 2026
Patent 12741001
COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION WITHOUT HLA MATCHING
7y 5m to grant Granted Sep 22, 2026
Patent 12703851
CELL CULTURE METHODS
4y 5m to grant Granted Aug 11, 2026
Patent 12688798
USE OF 3D-PRINTED FREESTANDING STRUCTURES FOR EX VIVO TISSUE
5y 8m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+50.8%)
Low
PTA Risk
Based on 494 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month